- Home
- SUPV vs SPRY Comparison
SUPV vs SPRY Comparison
Compare SUPV & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | SPRY |
|---|---|---|
| Founded | 1887 | 2015 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 788.5M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUPV | SPRY |
|---|---|---|
| Price | $9.45 | $8.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $13.00 | ★ $40.00 |
| AVG Volume (30 Days) | 806.0K | ★ 1.6M |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $86.20 | $87.40 |
| Revenue Next Year | $25.12 | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.54 | $6.66 |
| 52 Week High | $13.55 | $18.63 |
Technical Indicators
Market Signals| Indicator | SUPV | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 50.04 |
| Support Level | $7.75 | $7.82 |
| Resistance Level | $12.37 | $8.61 |
| Average True Range (ATR) | 0.57 | 0.59 |
| MACD | 0.16 | 0.06 |
| Stochastic Oscillator | 69.31 | 51.45 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.